{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T09:27:22Z","timestamp":1793698042248,"version":"4.5.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.clml.2026.07.017","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T23:30:50Z","timestamp":1785281450000},"page":"e1178-e1186","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hospital at Home for BCMA-Directed Bispecific Antibodies in Multiple Myeloma: A Multicenter Real-World Feasibility and Safety Study"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8930-0047","authenticated-orcid":false,"given":"Jeremie","family":"Zerbit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marguerite","family":"Vignon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3751-393X","authenticated-orcid":false,"given":"Guillemette","family":"Fouquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Detroit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Choquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6138-8112","authenticated-orcid":false,"given":"Laurent","family":"Garderet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Hermine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarisse","family":"Cazelles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Frenzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9463-2823","authenticated-orcid":false,"given":"Zoe","family":"Van De Wyngaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Harel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramy","family":"Rahme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathis","family":"Collier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederique","family":"Moufle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clement","family":"Leclaire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Bouscary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Winer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2026.07.017_bib0001","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2026.07.017_bib0002","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","article-title":"LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma","volume":"36","author":"Mateos","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2026.07.017_bib0003","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2026.07.017_bib0004","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2026.07.017_bib0005","doi-asserted-by":"crossref","first-page":"5898","DOI":"10.1182\/bloodadvances.2023010539","article-title":"Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis","volume":"7","author":"Reynolds","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.07.017_bib0006","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.clml.2024.05.002","article-title":"Risk of infection in patients with multiple myeloma treated with T-cell redirecting approaches: a call out for clinicians","volume":"24","author":"Lupia","year":"2024","journal-title":"Clin Lymph Myel Leuk"},{"key":"10.1016\/j.clml.2026.07.017_bib0007","article-title":"Preemptive immunoglobulin prophylaxis reduces infections in patients treated with anti-BCMA bispecific antibodies","volume":"26","author":"Piron","year":"2026","journal-title":"Clin Lymph Myel Leuk"},{"key":"10.1016\/j.clml.2026.07.017_bib0008","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41408-023-00879-7","article-title":"Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel","volume":"13","author":"Raje","year":"2023","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2026.07.017_bib0009","doi-asserted-by":"crossref","DOI":"10.1056\/CAT.23.0344","article-title":"The case for decentralizing cancer care: the rural oncology home","volume":"5","author":"Swenson","year":"2024","journal-title":"NEJM Catalyst"},{"key":"10.1016\/j.clml.2026.07.017_bib0010","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2025.1560027","article-title":"Cancer care delivery during the Paris 2024 olympic and paralympic games: lessons from a crisis-driven hospital at home program","volume":"12","author":"Zerbit","year":"2025","journal-title":"Front Med"},{"key":"10.1016\/j.clml.2026.07.017_bib0011","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1093\/annonc\/mdv563","article-title":"Home administration of bortezomib in multiple myeloma is cost-effective and is preferred by patients compared with hospital administration: results of a prospective single-center study","volume":"27","author":"Lassalle","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2026.07.017_bib0012","first-page":"973","article-title":"Management of patients with multiple myeloma in the era of COVID-19 pandemic: how hospital at home changes our medical practice","volume":"30","author":"Fouquet","year":"2022","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clml.2026.07.017_bib0013","doi-asserted-by":"crossref","DOI":"10.1200\/OA-25-00077","article-title":"Prognostic factors influencing the efficacy and safety of teclistamab and elranatamab in multiple myeloma: a multicenter propensity-weighted analysis","volume":"3","author":"Zerbit","year":"2026","journal-title":"JCO Oncol Adv"},{"key":"10.1016\/j.clml.2026.07.017_bib0014","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2026.07.017_bib0015","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1038\/s41375-018-0133-x","article-title":"A predictive model for risk of early grade\u2009\u2265\u20093 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial","volume":"32","author":"Dumontet","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2026.07.017_bib0016","doi-asserted-by":"crossref","first-page":"906","DOI":"10.3324\/haematol.2023.283590","article-title":"The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma","volume":"109","author":"Hammons","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2026.07.017_bib0017","doi-asserted-by":"crossref","unstructured":"Perrot A, Hulin C, Boumendil A, et al. Teclistamab in relapsed refractory multiple myeloma: a multi-institutional real-world study from the French early access program. Haematologica. DOI: 10.3324\/haematol.2024.286118.","DOI":"10.3324\/haematol.2024.286118"},{"key":"10.1016\/j.clml.2026.07.017_bib0018","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.29067","article-title":"Remote vs in-home physician visits for hospital-level care at home: a randomized clinical trial","volume":"5","author":"Levine","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clml.2026.07.017_bib0019","doi-asserted-by":"crossref","first-page":"109","DOI":"10.7326\/M23-2264","article-title":"Acute hospital care at home in the United States: the early national experience","volume":"177","author":"Levine","year":"2024","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clml.2026.07.017_bib0020","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1007\/s12325-023-02738-0","article-title":"Comparative effectiveness of teclistamab versus real-world physician\u2019s choice of therapy in LocoMMotion and MoMMent in triple-class exposed relapsed\/refractory multiple myeloma","volume":"41","author":"Moreau","year":"2024","journal-title":"Adv Ther"},{"key":"10.1016\/j.clml.2026.07.017_bib0021","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1080\/10428194.2024.2313628","article-title":"A matching-adjusted indirect comparison of the efficacy of elranatamab versus teclistamab in patients with triple-class exposed\/refractory multiple myeloma","volume":"65","author":"Mol","year":"2024","journal-title":"Leuk Lymph"},{"key":"10.1016\/j.clml.2026.07.017_bib0022","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMsa2206117","article-title":"The safety of Inpatient health care","volume":"388","author":"Bates","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2026.07.017_bib0023","first-page":"1707","article-title":"A specialized home care intervantion improves survival among older post-surgical cancer patients","author":"McCorkle","year":"2000","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.clml.2026.07.017_bib0024","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1547-5069.2000.00025.x","article-title":"Information needs of elderly postsurgical cancer patients during the transition from hospital to home","volume":"32","author":"Hughes","year":"2000","journal-title":"J Nurs Scholarsh"},{"key":"10.1016\/j.clml.2026.07.017_bib0025","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s11606-018-4307-z","article-title":"Hospital-level care at home for acutely ill adults: a pilot randomized controlled trial","volume":"33","author":"Levine","year":"2018","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.clml.2026.07.017_bib0026","first-page":"1","article-title":"Home management of acute medical complications in cancer patients: a prospective pilot study","volume":"24","author":"Font","year":"2016","journal-title":"Support Care Cancer"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026002429?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026002429?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T08:35:23Z","timestamp":1793694923000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026002429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2152265026002429"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.07.017","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hospital at Home for BCMA-Directed Bispecific Antibodies in Multiple Myeloma: A Multicenter Real-World Feasibility and Safety Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.07.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}